The angiotensin IV analog Nle-Tyr-Leu-ψ-(CH2-NH 2)3-4-His-Pro-Phe (Norleual) can act as a hepatocyte growth factor/c-met inhibitor

Journal of Pharmacology and Experimental Therapeutics

Volumn 333, Issue 1, 2010, Pages 161-173

  Yamamoto, B J ^a,b   Elias, P D ^a,b   Masino, J A ^a   Hudson, B D ^a,b   McCoy, A T ^a,b   Anderson, Z J ^a   Varnum, M D ^a   Sardinia, M F ^a,b,c   Wright, J W ^a,b   Harding, J W ^a,b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Pacific Northwest Biotechnology LLC   (United States)

^c WHITWORTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOTENSIN II [3-8]; ANTINEOPLASTIC AGENT; NORLEUAL; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN HEK293; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ANGIOTENSIN II; ANIMALS; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOGS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEPATOCYTE GROWTH FACTOR; HUMANS; LUNG; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; OLIGOPEPTIDES; PROTO-ONCOGENE PROTEINS C-MET; RADIOLIGAND ASSAY; SIGNAL TRANSDUCTION;

EID: 77949692477     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.161711     Document Type: Article

References (40)

1. Albiston AL, McDowall SG, Matsacos D, Sim P, Clune E, Mustafa T, Lee J, Mendelsohn FA, Simpson RJ, Connolly LM, et al. (2001) Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem 276:48623-48626.
2. Basilico C, Arnesano A, Galluzzo M, Comoglio PM, and Michieli P (2008) A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met. J Biol Chem 283:21267-21277.
3. Chen JK, Zimpelmann J, Harris RC, and Burns KD (2001) Angiotensin IV induces tyrosine phosphorylation of focal adhesion kinase and paxillin in proximal tubule cells. Am J Physiol Renal Physiol 280:F980-F988.
4. Chirgadze DY, Hepple JP, Zhou H, Byrd RA, Blundell TL, and Gherardi E (1999) Crystal structure of the NK1 fragment of HGF/SF suggests a novel mode for growth factor dimerization and receptor binding. Nat Struct Biol 6:72-79.
5. Comoglio PM, Giordano S, and Trusolino L (2008) Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 7:504-516.
6. Corso S, Comoglio PM, and Giordano S (2005) Cancer therapy: can the challenge be MET? Trends Mol Med 11:284-292.
7. Corso S, Migliore C, Ghiso E, De Rosa G, Comoglio PM, and Giordano S (2008) Silencing the MET oncogene leads to regression of experimental tumors and metastases. Oncogene 27:684-693.
8. Davis CJ, Kramár EA, De A, Meighan PC, Simasko SM, Wright JW, and Harding JW (2006) AT4 receptor activation increases intracellular calcium influx and induces a non-N-methyl-D-aspartate dependent form of long-term potentiation. Neuroscience 137:1369-1379.
9. Esteban V, Ruperez M, Sánchez-López E, Rodríguez- Vita J, Lorenzo O, Demaegdt H, Vanderheyden P, Egido J, and Ruiz-Ortega M (2005) Angiotensin IV activates the nuclear transcription factor-kappaB and related proinflammatory genes in vascular smooth muscle cells. Circ Res 96:965-973.
10. Ferraro D, Corso S, Fasano E, Panieri E, Santangelo R, Borrello S, Giordano S, Pani G, and Galeotti T (2006) Pro-metastatic signaling by c-Met through RAC-1 and reactive oxygen species (ROS). Oncogene 25:3689-3698.
11. Gherardi E, Sandin S, Petoukhov MV, Finch J, Youles ME, Ofverstedt LG, Miguel RN, Blundell TL, Vande Woude GF, Skoglund U, et al. (2006) Structural basis of hepatocyte growth factor/scatter factor and MET signalling. Proc Natl Acad Sci USA 103:4046-4051.
12. Handa RK (2001) Characterization and signaling of the AT(4) receptor in human proximal tubule epithelial (HK-2) cells. J Am Soc Nephrol 12:440-449.
13. Handa RK, Krebs LT, Harding JW, and Handa SE (1998) Angiotensin IV AT4-receptor system in the rat kidney. Am J Physiol 274:F290-F299.
14. Higuchi O and Nakamura T (1991) Identification and change in the receptor for hepatocyte growth factor in rat liver after partial hepatectomy or induced hepatitis. Biochem Biophys Res Commun 176:599-607.
15. Knudsen BS and Vande Woude G (2008) Showering c-MET-dependent cancers with drugs. Curr Opin Genet Dev 18:87-96.
16. Kramár EA, Armstrong DL, Ikeda S, Wayner MJ, Harding JW, and Wright JW (2001) The effects of angiotensin IV analogs on long-term potentiation within the CA1 region of the hippocampus in vitro. Brain Res 897:114-121.
17. Kramár EA, Harding JW, and Wright JW (1997) Angiotensin II- and IV-induced changes in cerebral blood flow. Roles of AT1, AT2, and AT4 receptor subtypes. Regul Pept 68:131-138.
18. Kuba K, Matsumoto K, Date K, Shimura H, Tanaka M, and Nakamura T (2000) HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 60:6737-6743.
19. Laustsen PG, Vang S, and Kristensen T (2001) Mutational analysis of the active site of human insulin-regulated aminopeptidase. Eur J Biochem 268:98-104.
20. Lee JH, Gao CF, Lee CC, Kim MD, and Vande Woude GF (2006a) An alternatively spliced form of Met receptor is tumorigenic. Exp Mol Med 38:565-573.
21. Lee KH, Choi EY, Hyun MS, Jang BI, Kim TN, Kim SW, Song SK, Kim JH, and Kim JR (2006b) Hepatocyte growth factor/c-met signaling in regulating urokinase plasminogen activator in human stomach cancer: a potential therapeutic target for human stomach cancer. Korean J Intern Med 21:20-27.
22. Lew RA, Mustafa T, Ye S, McDowall SG, Chai SY, and Albiston AL (2003) Angiotensin AT4 ligands are potent, competitive inhibitors of insulin regulated aminopeptidase (IRAP). J Neurochem 86:344-350.
23. Li YD, Block ER, and Patel JM (2002) Activation of multiple signaling modules is critical in angiotensin IV-induced lung endothelial cell proliferation. Am J Physiol Lung Cell Mol Physiol 283:L707-L716.
24. Ma PC, Maulik G, Christensen J, and Salgia R (2003) c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 22:309-325.
25. Michieli P, Mazzone M, Basilico C, Cavassa S, Sottile A, Naldini L, and Comoglio PM (2004) Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6:61-73.
26. Parr C and Jiang WG (2001) Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells. Int J Oncol 19:857-863.
27. Sakkab D, Lewitzky M, Posern G, Schaeper U, Sachs M, Birchmeier W, and Feller SM (2000) Signaling of hepatocyte growth factor/scatter factor (HGF) to the small GTPase Rap1 via the large docking protein Gab1 and the adapter protein CRKL. J Biol Chem 275:10772-10778.
28. Shimamura M, Sato N, Waguri S, Uchiyama Y, Hayashi T, Iida H, Nakamura T, Ogihara T, Kaneda Y, and Morishita R (2006) Gene transfer of hepatocyte growth factor gene improves learning and memory in the chronic stage of cerebral infarction. Hypertension 47:742-751.
29. Stella MC and Comoglio PM (1999) HGF: a multifunctional growth factor controlling cell scattering. Int J Biochem Cell Biol 31:1357-1362.
30. Swanson GN, Hanesworth JM, Sardinia MF, Coleman JK, Wright JW, Hall KL, Miller-Wing AV, Stobb JW, Cook VI, and Harding EC (1992) Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptor. Regul Pept 40:409-419.
31. Tolbert WD, Daugherty J, Gao C, Xie Q, Miranti C, Gherardi E, Woude GV, and Xu HE (2007) A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist. Proc Natl Acad Sci USA 104:14592-14597.
32. Vinh A, Widdop RE, Drummond GR, and Gaspari TA (2008) Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice. Cardiovasc Res 77:178-187.
33. Wagh PK, Peace BE, and Waltz SE (2008) Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. Adv Cancer Res 100:1-33.
34. Wajih N and Sane DC (2003) Angiostatin selectively inhibits signaling by hepatocyte growth factor in endothelial and smooth muscle cells. Blood 101:1857-1863.
35. Webb CP, Hose CD, Koochekpour S, Jeffers M, Oskarsson M, Sausville E, Monks A, and Vande Woude GF (2000) The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activatorplasmin proteolytic network. Cancer Res 60:342-349.
36. Wright JW, Jensen LL, Roberts KA, Sardinia MF, and Harding JW (1989) Structurefunction analyses of brain angiotensin control of pressor action in rats. Am J Physiol 257:R1551-R1557.
37. Wright JW, Stubley L, Pederson ES, Kramár EA, Hanesworth JM, and Harding JW (1999) Contributions of the brain angiotensin IV-AT4 receptor subtype system to spatial learning. J Neurosci 19:3952-3961.
38. Wright JW, Yamamoto BJ, and Harding JW (2008) Angiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets. Prog Neurobiol 84:157-181.
39. Youles M, Holmes O, Petoukhov MV, Nessen MA, Stivala S, Svergun DI, and Gherardi E (2008) Engineering the NK1 fragment of hepatocyte growth factor/ scatter factor as a MET receptor antagonist. J Mol Biol 377:616-622.
40. Zhang YW and Vande Woude GF (2003) HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem 88:408-417.